Neuroendocrine Tumor (NET) Treatment Market – By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy), Indication (Lungs NET, Pancreatic NET, Gastrointestinal NET), Route of Administration (Oral, Parenteral), End-use, & Global Forecast 2024 – 2032

Neuroendocrine Tumor Treatment Market Size

Neuroendocrine Tumor Treatment Market size reached a valuation of USD 2.5 billion in 2023, with a projected CAGR of 9.1% between 2024 and 2032, fueled by the rising global incidence of neuroendocrine tumors (NETs).
 

Technological advancements in diagnostics have notably improved the early and accurate detection of historically challenging NETs. This enhanced detection has, in turn, heightened the demand for effective treatment options. Moreover, heightened awareness of NETs among healthcare providers and the public has translated into more patients seeking treatment. The market has also seen a boost from the introduction and approval of novel therapies, particularly targeted treatments, broadening the treatment landscape for patients.
 

Pharmaceutical companies' increased R&D investments have played a pivotal role in the market's expansion. Furthermore, bolstered by supportive government policies and funding, collaborations between academic institutions and biopharmaceutical firms are fast-tracking innovations in oncology, propelling market growth.
 

Neuroendocrine tumor (NET) treatment encompasses a range of medical approaches tailored to manage these tumors, which originate from neuroendocrine cells exhibiting characteristics of both hormone-producing endocrine cells and nerve cells. Treatment decisions are influenced by factors such as tumor type, location, stage, grade, and the patient's overall health.
 

Neuroendocrine Tumor Treatment Market Trends

• The increasing incidence of cancer significantly drives the neuroendocrine tumor (NET) treatment market. As the prevalence of various cancers rises globally, the detection of neuroendocrine tumors, often diagnosed in later stages due to their asymptomatic nature, has also increased.
   
• According to available data, the worldwide incidence and prevalence of neuroendocrine neoplasms (NENs) are estimated to be 6 per 100,000 and 35 per 100,000, respectively.
   
• The incidence of NETs has been rising steadily in North America, Asia, and Europe, with the most profound increase in North America. For instance, in the U.S., the incidence of NETs has increased more than sixfold over the last four decades, with a predominant rise in localized tumors. The current disease prevalence of NETs in the U.S. approximates 170,000 patients.
   
• This surge in cancer cases necessitates effective treatment options, thereby boosting the demand for specialized NET therapies.
   
• Consequently, pharmaceutical and biotechnology companies are intensifying their research and development efforts to innovate and expand the treatment portfolio for NETs, aiming to improve patient outcomes and address the growing healthcare burden associated with these tumors. This dynamic landscape fosters significant growth in the market.
   

Neuroendocrine Tumor Treatment Market Analysis

Based on therapy, the market is segmented into somatostatin analogs (SSAs), targeted therapy, chemotherapy, and other therapies. The somatostatin analogs segment dominated the market in 2023 and accounted for USD 1.5 billion.
 

• Somatostatin analogs dominate the neuroendocrine tumor (NET) treatment market due to their proven effectiveness in managing symptoms and slowing tumor progression.
   
• These drugs, which mimic the natural hormone somatostatin, effectively inhibit the release of growth hormones and other substances that can worsen NET symptoms. Their widespread use is driven by their dual role in symptom control and tumor growth suppression, offering a comprehensive treatment approach.
   
• Furthermore, the ongoing development of long-acting formulations has enhanced patient compliance and convenience, further strengthening their market position.

Based on indication, the neuroendocrine tumor treatment market is segmented into lungs NET, pancreatic NET, gastrointestinal NET, and other indications. The pancreatic NET segment dominated the market in 2023 with a market share of 38.5%.
 

• The incidence and prevalence of pancreatic neuroendocrine tumors (NETs) have been increasing, leading to a higher demand for effective treatments.
   
• Advancements in diagnostic techniques have enabled earlier detection and more accurate characterization of these tumors, driving the need for targeted therapies.
   
• Robust clinical research and a growing number of clinical trials focused on pancreatic NETs have expanded treatment options, contributing to the dominance of this segment.
   

Based on route of administration, the neuroendocrine tumor treatment market is segmented into oral and parenteral. The oral segment dominated the market in 2023 and is expected to witness growth at a CAGR of 8.8%.
 

• The oral segment holds a significant market share in the market, driven by the convenience and patient compliance associated with oral medications.
   
• This segment's growth is supported by the development of targeted therapies that can be administered orally, providing an alternative to traditional intravenous treatments.
   
• Additionally, the ease of administration without the need for clinical settings enhances patient adherence to treatment regimens, further solidifying the dominance of the oral segment in this market.
   

Based on end-use, the neuroendocrine tumor treatment market is segmented into hospitals & clinics, cancer treatment centers, and other end-users. The hospitals & clinics segment is anticipated to reach USD 2.8 billion by 2032.
 

• Hospitals and clinics hold a significant market share in the neuroendocrine tumor (NET) treatment market due to their advanced infrastructure, comprehensive healthcare services, and access to cutting-edge diagnostic and therapeutic technologies.
   
• These medical institutions are equipped with specialized multidisciplinary teams, including oncologists, endocrinologists, and radiologists, who provide tailored treatment plans for NET patients.
   
• Moreover, the presence of state-of-the-art facilities for imaging and pathology enhances accurate diagnosis and monitoring of NETs, contributing to better patient outcomes and fostering patient trust. This integrated approach and the capability to manage complex cases attract a higher patient volume, reinforces the dominance of hospitals and clinics in the market.

North America dominated the NET treatment market in 2023 with a revenue of USD 1.1 billion and is anticipated to reach USD 2.3 billion by 2032.
 

• A high prevalence of cancer in North America necessitates the development and adoption of innovative therapies. For instance, in 2018, there were an estimated 1.9 million new cancer cases and 693,000 cancer deaths in Northern America.
   
• Additionally, the region's advanced healthcare infrastructure, robust research and development activities, and the presence of leading pharmaceutical and biotechnology companies contribute to its market dominance.
   
• Moreover, strong regulatory framework and faster approval processes in the U.S. and Canada also facilitate the introduction of new neuroendocrine tumor treatment, enhancing their availability and uptake in the market.
   

The U.S. neuroendocrine tumor treatment market is anticipated to grow at a CAGR of 8.7% between 2024 - 2032.
 

• As a leader in biomedical research and pharmaceutical innovation, the U.S. benefits from robust investment in biotechnology and a favorable regulatory environment that supports new drug development.
   
• Additionally, the country's extensive network of research institutions, academic centers, and pharmaceutical companies fosters collaboration and accelerates advancements in market.
   

Germany is anticipated to witness robust growth in the global neuroendocrine tumor treatment market.
 

• As a hub for biomedical research and pharmaceutical innovation, Germany fosters a conducive environment for advancing therapies targeting neuroendocrine tumor.
   
• The country's robust healthcare infrastructure, coupled with substantial investments in biotechnology and biopharmaceutical sectors, positions it at the forefront of developing novel NET drugs.
   
• Additionally, Germany's proactive regulatory framework and strong emphasis on clinical trials accelerate the approval and adoption of new neuroendocrine tumor drugs, further boosting market expansion.
   

Asia Pacific region is anticipated to witness high growth in neuroendocrine tumor treatment market, growing at a CAGR of 9.6% over the analysis years.
 

• Rapidly increasing healthcare infrastructure, coupled with a growing awareness of neuroendocrine tumors, is enhancing early diagnosis and treatment adoption across countries such as China, India, and Japan.
   
• Additionally, a rising prevalence of these tumors, attributed to improved diagnostic capabilities and an aging population, is fueling demand for advanced therapeutic options.
   
• Further, the presence of major pharmaceutical companies and ongoing clinical research efforts in the region also contribute to its robust growth prospects, making the Asia Pacific a critical area for market expansion and investment in neuroendocrine tumor therapies.
   

Neuroendocrine Tumor Treatment Market Share

The competitive landscape of the market is characterized by the presence of several key players and a high degree of innovation driven by advancements in biotechnology and pharmaceuticals. Major companies such as Novartis AG, Pfizer Inc., and Ipsen Pharma are at the forefront, offering a range of treatment options including somatostatin analogs and targeted therapies. The market is witnessing increased investment in research and development to improve existing therapies and discover novel treatments, with a strong focus on enhancing efficacy and reducing side effects. Strategic collaborations, mergers, and acquisitions are common as companies aim to expand their portfolios and market reach.
 

Neuroendocrine Tumor Treatment Market Companies

Prominent players operating in the neuroendocrine tumor treatment industry include:

• AVEO Pharmaceuticals, Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb
• Eli Lilly & Company
• F. Hoffmann-La Roche Ltd.
• Hutchison MediPharma Limited
• Ipsen
• Jubilant Life Sciences Ltd.
• Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
• Novartis AG
• Pfizer Inc.
• Tarveda Therapeutics
   

Neuroendocrine Tumor Treatment Industry News:

• In December 2023, Bristol Myers Squibb (BMS) completed acquisition of RayzeBio, a clinical-stage radiopharmaceutical company. The acquisition brings RayzeBio's differentiated actinium-based radiopharmaceutical platform and pipeline of drug development programs to BMS's leading oncology franchise. This includes RayzeBio's lead program, RYZ101, which is in Phase 3 development for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and in early-stage development for the treatment of small cell lung cancer and potentially other tumor types. This helped the company expand its product portfolio.
   

The neuroendocrine tumor treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy

• Somatostatin analogs (SSAs)
• Targeted therapy
• Chemotherapy
• Other therapies

Market, By Indication

• Lungs NET
• Pancreatic NET
• Gastrointestinal NET
• Other indications

Market, By Route of Administration

• Oral
• Parenteral

Market, By End-Use

• Hospitals & clinics
• Cancer treatment centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa